[go: up one dir, main page]

IL131746A0 - Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same - Google Patents

Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Info

Publication number
IL131746A0
IL131746A0 IL13174698A IL13174698A IL131746A0 IL 131746 A0 IL131746 A0 IL 131746A0 IL 13174698 A IL13174698 A IL 13174698A IL 13174698 A IL13174698 A IL 13174698A IL 131746 A0 IL131746 A0 IL 131746A0
Authority
IL
Israel
Prior art keywords
homologous recombination
via homologous
vectors
accomplishing
same
Prior art date
Application number
IL13174698A
Other languages
English (en)
Inventor
Idec Pharmaceutica Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26697516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL131746(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/819,866 external-priority patent/US5830698A/en
Application filed filed Critical
Publication of IL131746A0 publication Critical patent/IL131746A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL13174698A 1997-03-14 1998-03-09 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same IL131746A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/819,866 US5830698A (en) 1997-03-14 1997-03-14 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US09/023,715 US5998144A (en) 1997-03-14 1998-02-13 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
PCT/US1998/003935 WO1998041645A1 (fr) 1997-03-14 1998-03-09 Procede pour integrer des genes a des sites specifiques dans des cellules de mammifere par recombinaison homologue et vecteurs utilises pour la mise en oeuvre de ce procede

Publications (1)

Publication Number Publication Date
IL131746A0 true IL131746A0 (en) 2001-03-19

Family

ID=26697516

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13174698A IL131746A0 (en) 1997-03-14 1998-03-09 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Country Status (21)

Country Link
US (3) US6413777B1 (fr)
EP (1) EP0981637B1 (fr)
JP (1) JP4128227B2 (fr)
CN (1) CN1175111C (fr)
AT (1) ATE296356T1 (fr)
AU (1) AU737155B2 (fr)
BR (1) BR9808584A (fr)
CA (1) CA2283740C (fr)
CZ (1) CZ293355B6 (fr)
DE (1) DE69830312T2 (fr)
ES (1) ES2242997T3 (fr)
ID (1) ID24565A (fr)
IL (1) IL131746A0 (fr)
IN (1) IN189732B (fr)
NO (1) NO994397L (fr)
PL (1) PL191251B1 (fr)
PT (1) PT981637E (fr)
RO (1) RO120148B1 (fr)
RU (1) RU2004107694A (fr)
TW (1) TWI232239B (fr)
WO (1) WO1998041645A1 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU737155B2 (en) * 1997-03-14 2001-08-09 Biogen Idec Inc. Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
EP2270234B1 (fr) 1997-12-08 2013-03-06 California Institute of Technology Procédé pour créer des séquences de polynucléotides et polypeptides
CA2358385C (fr) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
WO2000039302A2 (fr) 1998-12-31 2000-07-06 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
DK1297170T3 (en) * 2000-06-23 2016-03-14 Novozymes As A process for stable chromosomal integration of multiple copies of the genes
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
IL161988A0 (en) 2001-11-16 2005-11-20 Corporation Idec Pharmaceutica Polycistronic expression of antibodies
US7164056B2 (en) * 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
WO2004042007A2 (fr) * 2002-10-30 2004-05-21 University Of Iowa Research Foundation Vecteurs de ciblage de gene de cellules somatiques et procedes d'utilisation correspondants
CA2512647C (fr) * 2003-01-07 2013-10-08 Symphogen A/S Methode de production de proteines polyclonales de recombinaison
ATE426672T1 (de) * 2003-01-31 2009-04-15 Icon Genetics Gmbh Pflanzentransformation mit in-vivo-zusammenbau einer eigenschaft
DE10303937A1 (de) * 2003-01-31 2004-08-12 Icon Genetics Ag Pflanzentransformation mit Assemblierung einer gewünschten Sequenz in Vivo
GEP20094629B (en) 2003-03-19 2009-03-10 Biogen Idec Inc Nogo receptor binding protein
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR101351122B1 (ko) * 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
EP1639009B1 (fr) 2003-05-30 2013-02-27 Merus B.V. Bibliothèque de fragments fab pour préparer un mélange d'anticorps
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005000898A2 (fr) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Purification et synthese preferentielle de molecules de liaison
JP4751326B2 (ja) * 2003-09-04 2011-08-17 メダレックス インコーポレイテッド 発現ベクター
US8030833B2 (en) * 2003-09-19 2011-10-04 The Board Of Trustees Of The University Of Illinois Electron emission device incorporating free standing monocrystalline nanowires
US7344753B2 (en) * 2003-09-19 2008-03-18 The Board Of Trustees Of The University Of Illinois Nanostructures including a metal
US7935862B2 (en) * 2003-12-02 2011-05-03 Syngenta Participations Ag Targeted integration and stacking of DNA through homologous recombination
NZ548828A (en) 2004-01-20 2009-07-31 Merus B V Mixtures of binding proteins
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
ATE443870T1 (de) 2004-07-20 2009-10-15 Symphogen As Verfahren zur charakterisierung einer polyklonalen zellinie
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
KR20070100346A (ko) 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 크립토 결합 분자
CN100381573C (zh) * 2005-04-14 2008-04-16 北京天广实生物技术有限公司 快速构建目标基因高表达的哺乳动物细胞株的体系和方法
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
EP3138403A1 (fr) * 2005-08-09 2017-03-08 Revivicor, Inc. Ongulés transgéniques exprimant la ctla4-ig et leurs utilisations
AU2006311828B2 (en) 2005-11-04 2013-07-11 Biogen Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
WO2007064911A1 (fr) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anticorps anti-souris cd20 et leurs utilisations
EP2543384A3 (fr) 2005-12-02 2013-04-10 Biogen Idec MA Inc. Traitement des conditions impliquant la démyélinisation
US8669345B2 (en) 2006-01-27 2014-03-11 Biogen Idec Ma Inc. Nogo receptor antagonists
DK2099826T3 (da) 2007-01-05 2014-01-20 Univ Zuerich Anti-beta-amyloid-antistof og anvendelser deraf
NO2740744T3 (fr) 2007-01-09 2018-08-25
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
BRPI0806849A2 (pt) 2007-02-02 2015-06-23 Biogen Idec Inc Uso de semaforin 6a para a promoção de mielinização e diferenciação de oligodendrócitos
EP2205071B1 (fr) * 2007-10-11 2015-07-22 Biogen MA Inc. Antagonistes lingo-1 et agonistes trkb por leur utilisation dans le traitement du glaucome
WO2009061500A1 (fr) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Utilisation des antagonistes de lingo-4 dans le traitement d'états mettant en jeu une démyélination
CA2708776A1 (fr) * 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Procedes pour le remplacement sequentiel d'une zone ciblee par recombinaison homologue
CA2729961C (fr) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Anticorps anti-lingo, li113, li62 variant co2
KR101826224B1 (ko) 2008-09-30 2018-02-06 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
EP2411412B1 (fr) 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Anticorps humanisés dirigés contre le polypeptide light et leurs utilisations
EP2484761A4 (fr) 2009-10-01 2013-11-27 Toto Ltd Construction d'adn, et procédé de production d'une cellule cho recombinante l'utilisant
NZ601171A (en) 2010-03-31 2014-11-28 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US20130053552A1 (en) * 2010-04-30 2013-02-28 Temasek Life Sciences Laboratory Limited Fragment switch: a reverse genetic approach
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
EP2640743B1 (fr) 2010-11-16 2016-10-05 Excelimmune, Inc. Procédés de production de protéines recombinantes
JP5209693B2 (ja) * 2010-12-10 2013-06-12 ロンザ・バイオロジクス・ピーエルシー Ｃｈｏ細胞において組換えタンパク質を発現する方法
CA2818781C (fr) 2010-12-17 2019-10-08 Neurimmune Holding Ag Anticorps humains anti-sod1
EA030777B9 (ru) 2011-06-23 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Анти-альфа-синуклеинсвязывающие молекулы
WO2013012733A1 (fr) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
AU2013251558B2 (en) 2012-04-25 2019-01-03 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
US20150238602A1 (en) 2012-10-09 2015-08-27 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
EP3792278A3 (fr) 2012-12-21 2021-05-26 Biogen MA Inc. Anticorps anti-tau humains
EP3517545A1 (fr) 2012-12-31 2019-07-31 Neurimmune Holding AG Anticorps humains recombinants pour la thérapie et la prévention de maladies associées au virus du polyome
WO2014127215A1 (fr) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Gène du facteur viii optimisé
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
EP3160478A4 (fr) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Gène du facteur ix optimisé
AU2015295441B2 (en) 2014-07-29 2020-05-14 Neurimmune Holding Ag Human-derived anti-huntingtin (HTT) antibodies and uses thereof
BR112017006598A2 (en) 2014-09-30 2018-04-17 Neurimmune Holding Ag human derived antidipeptide repeat antibody (dprs)
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2016112270A1 (fr) 2015-01-08 2016-07-14 Biogen Ma Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
CN106191040B (zh) * 2015-04-30 2021-09-14 杭州菁因康生物科技有限公司 基因打靶方法
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
LT3411478T (lt) 2016-02-01 2022-09-26 Bioverativ Therapeutics Inc. Optimizuoti viii faktoriaus genai
WO2017214376A1 (fr) 2016-06-10 2017-12-14 Elwha Llc Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline membranaire différente d'une immunoglobuline sécrétée et fonction cytolytique
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
AU2017297404A1 (en) 2016-07-13 2019-01-24 Biogen Ma Inc. Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
CA3051862A1 (fr) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Proteine de fusion du facteur ix et procedes de fabrication et d'utilisation associes
IL322212A (en) 2017-08-09 2025-09-01 Bioverativ Therapeutics Inc Nucleic acid molecules and their uses
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
WO2019210054A1 (fr) 2018-04-27 2019-10-31 Biogen Ma Inc. Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
CN110607326B (zh) * 2018-06-15 2022-11-29 江苏省农业科学院 非强启动式的外源基因表达法及其在具有毒性的目标蛋白表达中的应用
CN113227385B (zh) 2018-08-09 2024-12-24 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
SG11202103111TA (en) * 2018-10-01 2021-04-29 Lonza Ag Ssi cells with predictable and stable transgene expression and methods of formation
JP7208380B2 (ja) 2018-10-26 2023-01-18 エフ．ホフマン－ラ ロシュ アーゲー リコンビナーゼ媒介性カセット交換を使用した多重特異性抗体スクリーニング法
CN113795513B (zh) 2019-02-13 2025-02-18 布里格姆妇女医院 抗外周淋巴结地址素抗体及其用途
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
CA3173521A1 (fr) 2020-02-28 2021-09-02 The Brigham And Women's Hospital, Inc. Modulation selective de signalisation de la superfamille du facteur de croissance transformant beta par le biais d'anticorps multi-specifiques
CA3183557A1 (fr) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Procedes pour retirer le facteur viii a l'etat libre contenu dans des preparations de vecteurs lentiviraux modifies pour exprimer ladite proteine
MX2024002334A (es) 2021-08-23 2024-05-23 Bioverativ Therapeutics Inc Genes optimizados del factor viii.
AR126845A1 (es) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc Producción de adn de extremo cerrado con secuencias repetidas de terminal invertida
CN118019758A (zh) 2021-09-30 2024-05-10 比奥维拉迪维治疗股份有限公司 编码免疫原性降低的因子viii多肽的核酸
AR134366A1 (es) 2023-11-15 2026-01-07 Neurimmune Ag Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1991006667A1 (fr) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production de proteines par recombinaison homologue
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
WO1993024642A1 (fr) * 1992-06-04 1993-12-09 Exemplar Corporation Insertion d'adn heterologue en dehors de genes chromosomiques connus
MX9305183A (es) * 1992-08-27 1994-05-31 Us Agriculture Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
AU737155B2 (en) * 1997-03-14 2001-08-09 Biogen Idec Inc. Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Also Published As

Publication number Publication date
CZ293355B6 (cs) 2004-04-14
US20040166528A1 (en) 2004-08-26
US6841383B2 (en) 2005-01-11
PT981637E (pt) 2005-09-30
ATE296356T1 (de) 2005-06-15
JP4128227B2 (ja) 2008-07-30
US20020192820A1 (en) 2002-12-19
CZ316299A3 (cs) 2000-02-16
PL191251B1 (pl) 2006-04-28
EP0981637B1 (fr) 2005-05-25
TWI232239B (en) 2005-05-11
AU6443598A (en) 1998-10-12
AU737155B2 (en) 2001-08-09
ID24565A (id) 2000-07-27
IN189732B (fr) 2003-04-19
CA2283740A1 (fr) 1998-09-24
PL335695A1 (en) 2000-05-08
DE69830312D1 (de) 2005-06-30
US7235360B2 (en) 2007-06-26
CN1255166A (zh) 2000-05-31
CA2283740C (fr) 2006-06-27
ES2242997T3 (es) 2005-11-16
NO994397L (no) 1999-11-09
CN1175111C (zh) 2004-11-10
EP0981637A1 (fr) 2000-03-01
JP2001516221A (ja) 2001-09-25
US6413777B1 (en) 2002-07-02
RU2004107694A (ru) 2005-08-27
WO1998041645A1 (fr) 1998-09-24
RO120148B1 (ro) 2005-09-30
NO994397D0 (no) 1999-09-10
BR9808584A (pt) 2000-05-23
DE69830312T2 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
IL131746A0 (en) Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
MY137837A (en) Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
DK1097211T3 (da) Ekspression af eukaryote peptider i planteplastider
ATE303448T1 (de) Duale selektionkassette und sie enthaltende plasmide
CA2203569A1 (fr) Sequence nucleotidique codant l'enzyme i-scei et ses utilisations
HUP9700428A2 (hu) Célsejtspecifikus vektorok gének beépítésére, a vektorokat tartalmazó gyógyászati készítmények és azok alkalmazása
SG48099A1 (en) Adeno-associated viral (aav) liposomes and methods related thereto
WO1999015682A3 (fr) Materiels et procedes destines a rendre silencieux un gene
NO964445D0 (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
EP1200557A4 (fr) Procede de fabrication de chromosomes artificiels de plantes
MX9709317A (es) Cromosomas sinteticos de mamifero y metodos para su construccion.
WO2002006457A3 (fr) Genes de lipase
ATE526818T1 (de) Gentechnisch hergestellte wasserlinse
ATE244311T1 (de) Expressionssystem von antikörpern bei homologischer rekombinierung in murinezellen
AU5659898A (en) Gene-trapping construct for the identification and isolation of genes
WO1999021976A3 (fr) Generation rapide de lignees cellulaires mammiferes stables produisant des niveaux eleves de proteines recombinantes
Yoneda et al. Cloning of a foreign gene coding for α-amylase in Bacillussubtilis
EP2298911A3 (fr) Procédés de production de polypeptides dans des cellules presentant une déficience réspiratoire
AU1814995A (en) Galanin receptor, nucleic acids, transformed cells and uses thereof
WO2001079512A3 (fr) Vecteur et methode pour remplacement et interruption cibles d'une sequence d'adn integree
WO1994016074A3 (fr) Interleukine-14 facteur de croissance des lymphocytes b de masse moleculaire elevee
ES8802251A1 (es) Un procedimiento para preparar un microorganismo hospedante transformado del genero sacharomyces.
EP0258046A3 (fr) Procédé de tri pour streptomyces contenant l'ADN recombinante et pour d'autres cellules-hôtes
EP0174096A3 (fr) Vecteurs pour l'introduction d'ADN dans les chromosomes d'une bactérie ou pour la suppression d'ADN de celle-ci et pour la production de protéine
WO2000037682A8 (fr) Procede permettant d'accroitre l'expression d'un gene etranger

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees